A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

NCT01789736 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

234

Enrollment

INDUSTRY

Sponsor class

Conditions

Open Angle Glaucoma
Ocular Hypertension

Interventions

DRUG: PG286 Ophthalmic Solution 0.5%
DRUG: AR-12286 Ophthalmic Solution 0.5%
DRUG: Travoprost Ophthalmic Solution 0.004%

Sponsor

Aerie Pharmaceuticals